XORTX Therapeutics Inc. (XRTX.V)

CAD 1.62

(-7.43%)

Long Term Debt Summary of XORTX Therapeutics Inc.

XORTX Therapeutics Inc.'s latest annual long term debt in 2023 was - CAD , down -100.0% from previous year.
XORTX Therapeutics Inc.'s latest quarterly long term debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
XORTX Therapeutics Inc. reported annual long term debt of 11.48 Thousand CAD in 2022, down 0.0% from previous year.
XORTX Therapeutics Inc. reported annual long term debt of - CAD in 2021, down 0.0% from previous year.
XORTX Therapeutics Inc. reported quarterly long term debt of - USD for 2024 Q2, down 0.0% from previous quarter.
XORTX Therapeutics Inc. reported quarterly long term debt of - USD for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of XORTX Therapeutics Inc. (2023 - 2014)

Historical Annual Long Term Debt of XORTX Therapeutics Inc. (2023 - 2014)

Year	Long Term Debt	Long Term Debt Growth
2023	- CAD	-100.0%
2022	11.48 Thousand CAD	0.0%
2021	- CAD	0.0%
2020	- CAD	0.0%
2019	- CAD	-100.0%
2018	43.25 Thousand CAD	20.93%
2017	35.76 Thousand CAD	0.0%
2016	- CAD	0.0%
2014	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- USD	0.0%
2024 Q2	- USD	0.0%
2023 Q4	- USD	0.0%
2023 FY	- CAD	-100.0%
2023 Q1	- USD	-100.0%
2023 Q2	- USD	0.0%
2023 Q3	- USD	0.0%
2022 Q1	- CAD	0.0%
2022 Q4	15.58 Thousand CAD	-59.63%
2022 FY	11.48 Thousand CAD	0.0%
2022 Q3	38.61 Thousand CAD	-36.9%
2022 Q2	61.2 Thousand CAD	0.0%
2021 Q4	- CAD	0.0%
2021 Q3	- CAD	0.0%
2021 Q2	- CAD	0.0%
2021 FY	- CAD	0.0%
2021 Q1	- CAD	0.0%
2020 FY	- CAD	0.0%
2020 Q2	- CAD	0.0%
2020 Q1	- CAD	0.0%
2020 Q4	- CAD	0.0%
2020 Q3	- CAD	0.0%
2019 Q2	47 Thousand CAD	4.15%
2019 FY	- CAD	-100.0%
2019 Q1	45.13 Thousand CAD	4.35%
2019 Q4	- CAD	-100.0%
2019 Q3	48.9 Thousand CAD	4.04%
2018 Q4	43.25 Thousand CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q3	- CAD	0.0%
2018 Q1	- CAD	-100.0%
2018 FY	43.25 Thousand CAD	20.93%
2017 Q2	- CAD	0.0%
2017 Q4	35.76 Thousand CAD	0.0%
2017 FY	35.76 Thousand CAD	0.0%
2017 Q1	- CAD	0.0%
2017 Q3	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q1	- CAD	0.0%
2016 FY	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%

Peer Long Term Debt Comparison of XORTX Therapeutics Inc.

Name	Long Term Debt	Long Term Debt Difference
Arch Biopartners Inc.	703.92 Thousand CAD	100.0%
Covalon Technologies Ltd.	919.08 Thousand CAD	100.0%
Hemostemix Inc.	4.32 Million CAD	100.0%
Universal Ibogaine Inc.	1.73 Million CAD	100.0%
Kane Biotech Inc.	1.3 Million CAD	100.0%
MedMira Inc.	2.95 Million CAD	100.0%
Marvel Biosciences Corp.	1 Million CAD	100.0%
NervGen Pharma Corp.	105.6 Thousand CAD	100.0%